N4 Pharma to host webinar on collaboration agreement with SRI International

N4 Pharma
[shareaholic app="share_buttons" id_name="post_below_content"]

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, will provide a pre-recorded webinar relating to the Company’s recent Collaboration Agreement with SRI International Inc. which was announced on 25 April 2024.

The webinar will be available for viewing on 7 May 2024 at 10:00 BST, via the Company’s Investor Hub.

Investors will be notified via email of the presentation if they have signed up to the Investor Hub in advance, which can be done here: investors.n4pharma.com/auth/signup.

Investors are invited to submit questions in advance via N4 Pharma’s Investor Hub, and CEO Nigel Theobald will address as many as possible. Register and submit questions at: investors.n4pharma.com

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies for cancer and vaccines.
    N4 Pharma Plc (LON:N4P) unveils its audited results for 2023, showcasing advancements in its innovative Nuvec® delivery system for cancer treatments and vaccines.
    N4 Pharma Plc (LON:N4P) updates on successful oral delivery research for Nuvec® system, showing potential for cancer treatment and vaccines. CEO Nigel Theobald shares insights.
    N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments.
    N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its global portfolio of granted patents.
    N4 Pharma's subsidiary, Nanogenics, has signed a contract to prepare its ECP105 product for pre-clinical studies in Glaucoma treatment.

      Search

      Search